| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Nuclear Medicine, Surgery and Diagnostic Radiology, University Hospital of Ulm, Ulm, Germany
Correspondence: For correspondence or reprints contact: Sven N. Reske, MD, Abteilung Nuklearmedizin, Klinikum der Universität Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany.
ABSTRACT
We evaluated the potential of the glucose analog [18F]fluorodeoxyglucose (FDG) as a PET tracer for the hepatic staging in 168 patients designated for resective pancreatic surgery. Methods: Metastatic liver disease was confirmed or excluded during surgery or with CT follow-up for at least 6 mo. Proven metastases were then retrospectively identified on preoperative CT (gold standard). Hepatic PET scans of all patients were interpreted blindly. Any focal FDG uptake was considered malignant. Both proven hepatic metastases and suspicious hepatic PET lesions were then compared, lesion by lesion, with CT. Standardized uptake values (SUV) and tumor-to-liver ratios (T/L) were determined for the most intense lesion of each patient. Results: Sensitivity of FDG PET was 68% (15 of 22 patients). The lesion detection rate was 97% (28 of 29 metastases) for lesions >1 cm and 43% (16 of 37 metastases) for lesions 
1 cm. Specificity was 95% (138 of 146 patients). Six of eight patients with false-positive results had marked intrahepatic cholestasis (versus 3 of 15 patients with true-positive lesions), one had an infrahepatic abscess and one had a right basal pulmonary metastasis. The SUV and T/L were 4.6 ± 1.4 and 2.3 ± 1.1, respectively, for malignant lesions and 4.1 ± 1.5 and 1.9 ± 0.3, respectively, for false-positivelesions and therefore are of limited value. Conclusion: FDG PET provides reliable hepatic staging for lesions > 1 cm. False-positive results are associated with the presence of marked intrahepatic cholestasis. For lesions 1 cm, FDG PET can define malignancy in 43% of suspicious CT lesions in the absence of dilated bile ducts.
Key Words: FDG PET • pancreatic cancer • liver metastases
This article has been cited by other articles:
|
|
 |
|
  J. M. Farma, A. A. Santillan, M. Melis, J. Walters, D. Belinc, D.-T. Chen, E. A. Eikman, and M. Malafa PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms Ann. Surg. Oncol., September 1, 2008; 15(9): 2465 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Miller, A. L. Keppke, D. Reddy, J. Huang, J. Jin, M. F. Mulcahy, and R. Salem Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET Am. J. Roentgenol., March 1, 2007; 188(3): 776 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Sahani, S. P. Kalva, A. J. Fischman, R. Kadavigere, M. Blake, P. F. Hahn, and S. Saini Detection of Liver Metastases from Adenocarcinoma of the Colon and Pancreas: Comparison of Mangafodipir Trisodium-Enhanced Liver MRI and Whole-Body FDG PET Am. J. Roentgenol., July 1, 2005; 185(1): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Kalra, M. M. Maher, G. W. Boland, S. Saini, and A. J. Fischman Correlation of Positron Emission Tomography and CT in Evaluating Pancreatic Tumors: Technical and Clinical Implications Am. J. Roentgenol., August 1, 2003; 181(2): 387 - 393. [Full Text] [PDF]
|
|
|
|
 |
|
 B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Kalady, B. M. Clary, L. A. Clark, M. Gottfried, E. M. Rohren, R. E. Coleman, T. N. Pappas, and D. S. Tyler Clinical Utility of Positron Emission Tomography in the Diagnosis and Management of Periampullary Neoplasms Ann. Surg. Oncol., October 1, 2002; 9(8): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Fuentes, C J Keith, M Griffiths, G Durbridge, and K A Miles Hepatic haemodynamics: interrelationships between contrast enhancement and perfusion on CT and Doppler perfusion indices Br. J. Radiol., January 1, 2002; 75(889): 17 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Eubank, D. A. Mankoff, H. J. Vesselle, J. F. Eary, E. K. Schubert, L. K. Dunnwald, S. K. Lindsley, J. R. Gralow, M. M. Austin-Seymour, G. K. Ellis, et al. Detection of Locoregional and Distant Recurrences in Breast Cancer Patients by Using FDG PET RadioGraphics, January 1, 2002; 22(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. H. Yu, C. T. Liew, W. Y. Lau, T. W. Leung, and C. Metreweli US-guided Percutaneous Biopsy of Small ({<=}1-cm) Hepatic Lesions Radiology, January 1, 2001; 218(1): 195 - 199. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. S. Newlands, P. J. Mulholland, L. Holden, M. J. Seckl, and G. J. S. Rustin Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors J. Clin. Oncol., February 14, 2000; 18(4): 854 - 854. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
